Texas Biomed leads transatlantic group in $23M HIV vaccine effort

Dr. Ruth Ruprecht, director of the Texas Biomed AIDS Research Program

An HIV vaccine research team led by Texas Biomedical Research Institute has secured $23 million in NIH grant funding to explore an approach that’ll utilize three lines of defense to protect against the virus.

As part of the 5-year project with three phases, the scientists want to develop a vaccine that can block HIV where it infiltrates the body at the mucosa while also creating a backup response throughout the blood and tissue.

First, the group will examine how HIV moves through mucus and mucosal fluids and how it passes through epithelial barriers. For the second portion, the group plans to build on previous work in immune exclusion to prevent the virus from crossing epithelial barrier. Lastly, Dr. Darrell Irvine from MIT will lead efforts in vaccine design.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The group takes inspiration for the plan from the military tactic “defense-in-depth” which stresses to protect an area even after a frontline is overrun, according to a release.

It’s the latest in a series of developments in a fast-moving HIV vaccines field as projects around the world take shape. In May, the NIH said it planned to initiate a large-scale trial later this year in South Africa, building on a 2009 study in Thailand of the vaccine RV144.

Just last week, Johnson & Johnson said it completed enrollment for a Phase I/IIa trial of 400 volunteers in South Africa, Rwanda, Uganda, Thailand and the United States, Business Insider reported. It also has plans to enroll for another early trial.

Elsewhere, Duke last year grabbed $20 million in NIH funding to conduct its HIV vaccine research, and TSRI, and the University of Maryland have all progressed with candidates. Last fall, the European Commission started a €23 million collaboration between 22 organizations and companies hoping to contribute in efforts toward an HIV vaccine.

- here's the release
- more from Business Insider

Related Articles:
NIH to launch large-scale HIV vaccine trial in South Africa
Duke, NIAID track HIV evolution with eyes on creating a vaccine
European Commission launches €23M HIV vaccine research initiative
HIV vaccine research a 'major advance,' NIH official says

Read more on

Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.